#ACC22 [Not published yet] – RCT: Mavacamten reduces the need for surgical intervention in patients with obstructive hypertrophic cardiomyopathy.

VALOR-HCM: Mavacamten Significantly Reduces Need For Surgical Intervention in Patients With Obstructive HCM – American College of Cardiology

Commentaries:

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM – TCTMD

Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy – VALOR-HCM – American College of Cardiology

Trial shows drug effective in nearly 80% of patients with hypertrophic cardiomyopathy – Cleveland Clinic

Related: #ESCCongress – Randomized trial: Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy

Commentary on Twitter

ICYMI: The VALOR-HCM trial at #ACC22 showed that mavacamten improved symptoms & significantly reduced eligibility for needing septal reduction therapy (SRT) among symptomatic patients with obstructive #cvHCM. Check out the Trial Summary here: https://t.co/fXVp8H0bw5 @DLBHATTMD pic.twitter.com/f0gPp9dNX8

— American College of Cardiology (@ACCinTouch) April 2, 2022